# REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

> **NCT05902533** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Cincinnati** · enrollment: 33 (estimated)

## Conditions studied

- Anal Cancer

## Interventions

- **RADIATION:** Radiation (reduced elective nodal dose (30.6 Gy)
- **DRUG:** Capecitabine
- **DRUG:** Mitomycin c

## Key facts

- **NCT ID:** NCT05902533
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-14
- **Primary completion:** 2026-08-14
- **Final completion:** 2029-08-14
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05902533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05902533, "REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05902533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*